DK1370288T3 - Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG - Google Patents

Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG

Info

Publication number
DK1370288T3
DK1370288T3 DK01996390.9T DK01996390T DK1370288T3 DK 1370288 T3 DK1370288 T3 DK 1370288T3 DK 01996390 T DK01996390 T DK 01996390T DK 1370288 T3 DK1370288 T3 DK 1370288T3
Authority
DK
Denmark
Prior art keywords
thrombocytopenia
ivig
monoclonal
producing
composition
Prior art date
Application number
DK01996390.9T
Other languages
English (en)
Inventor
Alan H Lazarus
John Freedman
Seng Song
Andrew R Crow
Original Assignee
Canadian Blood Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canadian Blood Services filed Critical Canadian Blood Services
Application granted granted Critical
Publication of DK1370288T3 publication Critical patent/DK1370288T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK01996390.9T 2000-11-20 2001-11-20 Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG DK1370288T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24944100P 2000-11-20 2000-11-20
PCT/CA2001/001648 WO2002040047A2 (en) 2000-11-20 2001-11-20 Method for treating thrombocytopenia with monoclonal ivig

Publications (1)

Publication Number Publication Date
DK1370288T3 true DK1370288T3 (da) 2012-03-05

Family

ID=22943488

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10178480.9T DK2283861T3 (da) 2000-11-20 2001-11-20 Fremgangsmåde til behandling af trombocytopeni med monoklonalt ivig
DK01996390.9T DK1370288T3 (da) 2000-11-20 2001-11-20 Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10178480.9T DK2283861T3 (da) 2000-11-20 2001-11-20 Fremgangsmåde til behandling af trombocytopeni med monoklonalt ivig

Country Status (7)

Country Link
US (1) US20040047862A1 (da)
EP (2) EP1370288B1 (da)
AT (1) ATE540694T1 (da)
AU (1) AU2002220404A1 (da)
CA (2) CA2467781C (da)
DK (2) DK2283861T3 (da)
WO (1) WO2002040047A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
US20080050391A1 (en) * 2004-03-30 2008-02-28 Lazarus Alan H Method for Treating Autoimmune Diseases With Antibodies
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8597636B2 (en) 2006-01-13 2013-12-03 Canadian Blood Services Method for treating autoimmune diseases and compositions therefor
MX2008012843A (es) 2006-04-05 2009-01-19 Univ Rockefeller Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados.
WO2009132130A2 (en) 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
US20150329639A1 (en) * 2012-12-12 2015-11-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
CN112142843B (zh) 2013-12-24 2024-10-18 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
MY188761A (en) 2015-03-09 2021-12-29 Argenx Bvba Method of reducing serum levels of fc-containing agents using fcrn antagonists
US12240875B2 (en) 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
CA3101462A1 (en) 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
CN114126647A (zh) 2019-06-07 2022-03-01 阿尔金克斯有限公司 适用于皮下施用的FcRn抑制剂的药物制剂
BR112022013554A2 (pt) 2020-01-08 2022-09-06 argenx BV Métodos para tratar distúrbios do pênfigo
CA3258000A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
GB202319605D0 (en) 2023-12-20 2024-01-31 argenx BV Monovalent binding molecules and methods of use
WO2025229224A1 (en) 2024-05-03 2025-11-06 argenx BV Monovalent anti-iga binding molecules and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993812A (en) * 1995-09-14 1999-11-30 Cangene Corporation Method of delaying the progression of an infection with the human immunodeficiency virus
JPH0987202A (ja) * 1995-09-20 1997-03-31 Sumitomo Pharmaceut Co Ltd 血液凝固異常治療剤
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
US5980893A (en) * 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
MXPA01011279A (es) * 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
CA2422076A1 (en) * 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
AUPR540301A0 (en) * 2001-06-01 2001-06-28 Walter And Eliza Hall Institute Of Medical Research, The A method of purification of cells

Also Published As

Publication number Publication date
EP1370288B1 (en) 2012-01-11
EP2283861B1 (en) 2016-01-27
EP2283861A3 (en) 2013-05-29
WO2002040047A3 (en) 2003-10-02
CA2467781A1 (en) 2002-05-23
CA2467781C (en) 2014-09-23
CA2856033C (en) 2015-11-03
WO2002040047A2 (en) 2002-05-23
EP1370288A2 (en) 2003-12-17
DK2283861T3 (da) 2016-02-15
US20040047862A1 (en) 2004-03-11
ATE540694T1 (de) 2012-01-15
CA2856033A1 (en) 2002-05-23
AU2002220404A1 (en) 2002-05-27
EP2283861A2 (en) 2011-02-16

Similar Documents

Publication Publication Date Title
DK1370288T3 (da) Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG
BRPI0511910A (pt) anticorpos antil-il-13 e complexos
WO2006113643A3 (en) High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
NZ626665A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
ATE447587T1 (de) Anti-il-20-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
TW200716677A (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
NZ601583A (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
TW200716182A (en) Antibodies directed to CD20 and uses thereof
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
NZ603883A (en) Method for preparing antibodies having improved properties
TW200637873A (en) Antibodies against interleukin-1 beta
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
DE60236016D1 (de) Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
TW200634027A (en) Antibodies directed to angiopoietin-2 and uses thereof
DK2374818T3 (da) Højaffinitetsantistoffer mod human IL-6-receptor
NZ590863A (en) Anti-hepcidin-25 selective antibodies and uses thereof
LT2005099A (en) Antibodies directed to monoclonal chemo-atractant protein-1 (mcp-1) and uses thereof
IL200129A0 (en) Regulatory t cell epitopes, compositions and uses thereof
DE60328747D1 (de) Reinigung von polyreaktiven Autoantikörpern und deren Verwendungen
RU2013123927A (ru) ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4α)-173
EP2522724A4 (en) POLYPEPTIDE MODIFYING METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
CY1112447T1 (el) Ανθρωπινα αντισωματα για την ιντερλευκινη (ιντεrleukin) 15 (il-15)
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13